- 期刊
Clinical Application of Inhaled Ciclesonide and Enoxaparin for COVID-19 Pneumonia
摘要
The novel coronavirus disease 2019 (COVID-19) pandemic is a threat to global public health. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and characterized by high transmission, high mortality, lack of effective treatment, and prolonged hospitalization. Currently, there is no clear management strategy for COVID-19 infection. Some clinical evidence suggests that the use of inhaled ciclesonide and enoxaparin subcutaneous injection maybe helpful for disease treatment. In this article, we report the successful treatment of a 65-year-old male with COVID-19 pneumonia with Inhaled corticosteroid and enoxaparin subcutaneously, which also shortened the course of the disease without significant complications.
延伸閱讀
- 邊苗瑛、龍芳、林佑穗、楊式興（2010）。Clinical Application of Extracorporeal Membrane Oxygenation。呼吸治療，9(1)，41-52。https://doi.org/10.6269/JRT.2010.9.1.05
- SCHWEINFURTH, J. M., & OSSOFF, R. H. (2000). Current Endoscopic Treatment of Dysphonia. Diagnostic and Therapeutic Endoscopy, 2000(), 87-90. https://doi.org/10.1155/DTE.6.87
- Wang, Y. C., Huang, W. C., Cheng, C. C., Hung, C. C., Kuo, F. Y., & Mar, G. Y. (2020). Managing Pulmonary Hypertension in Times of COVID-19. Acta Cardiologica Sinica, 36(4), 394-395. https://doi.org/10.6515/ACS.202007_36(4).20200619C
- 黃柏銘（2022）。Cases of Ma-Xing-Gan-Shi-Tang and NRICM101 in the Treatment of COVID-19 Pneumonia Comorbidities。中醫藥研究論叢，25()，43-50。https://doi.org/10.6516/TJTCM.202203/SP_25.0006
- 簡尚志、彭子安、王國慶、李主成（2013）。A Suspected Case of Co-Administration of Phenytoin with Capecitabine Induced Severe Adverse Drug Reaction。臺灣臨床藥學雜誌，21(2)，153-159。https://doi.org/10.6168/FJCP.2013.2102.07